ACTG launches phase 1 HIV cure study evaluating two promising therapies


Sumary of ACTG launches phase 1 HIV cure study evaluating two promising therapies:

  • The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5386, a phase 1 HIV cure study evaluating two promising therapies..
  • A5386 will study whether N-803 (a clinical-stage biologic also called Anktiva?) can control HIV alone or together with combination broadly neutralizing antibodies (bNAbs) after participants stop their antiretroviral therapy (ART) and they are carefully monitored..
  • In pre-clinical and clinical research, N-803 (an IL-15 superagonist) has exhibited three activities that may help the immune system eliminate HIV reservoirs or control virus rebound..
  • Finally, it enables NK cells and CD8+ T-cells to move to lymphoid tissues where they will encounter and hopefully eliminate HIV-infected cells..
  • A5386 will utilize an array of virologic and immunologic tests to evaluate the degree to which each of these expected activities are induced in study participants..
  • Ultimately, the study will test whether this approach results in immune control of HIV when ART is paused with careful monitoring..
  • A5386 is particularly exciting as it marries two of the approaches in the HIV cure research space with the most potential..
  • We believe this study will provide important insights as we continue to pursue our ultimate goal of identifying a cure for HIV and making it available to the millions of people living with HIV around the world.”…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.